Gilenya Increases Patient Infection Risk, Clinical Data Suggest

Gilenya Increases Patient Infection Risk, Clinical Data Suggest

292841

Gilenya Increases Patient Infection Risk, Clinical Data Suggest

The multiple sclerosis (MS) treatment Gilenya (fingolimod) is associated with a 16% greater risk of infections, compared with a placebo or control treatment, according to data from 12 randomized clinical trials. The findings were published in a study, “Incidence and Risk of Infection Associated With Fingolimod in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis of 8,448 Patients From 12 Randomized Controlled Trials,” in the journal Frontiers in Immunology. Gilenya is an oral treatment from…

You must be logged in to read/download the full post.